Living the Japanese bioventure (Pepti)dream
This article was originally published in Scrip
You may also be interested in...
Emerging Company Profile: Using IP licensed from Yale, Kleo is betting it can complement or replace existing immuno-oncology drugs, specifically Darzalex. In partnership with PeptiDream, it just unveiled its first candidate for clinical development.
Merck & Co is tapping government scientific researchers in Singapore to help overcome some of the limitations of macrocyclic peptide therapeutics.
Japanese major buys out existing cancer cell therapy research partner, exercising an exclusive option dating back to a 2017 collaboration and expanding its immuno-oncology ambitions and pipeline.